All In Biotech

Drug Trial Radar · NCT06450366

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Jul 8, 2024

Primary completion

Feb 14, 2025

Study completion Mar 28, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess whether enlicitide is superior to ezetimibe or bempedoic acid or ezetimibe + bempedoic acid in reducing low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia, and to evaluate its safety and tolerability. The primary study hypotheses are enlicitide is superior to ezetimibe, bempedoic acid, and ezetimibe + bempedoic acid on mean percent change from baseline in LDL-C at week 8.

Conditions

  • Hypercholesterolemia

Interventions

  • EnlicitideDrug

    Oral tablet

  • EzetimibeDrug

    Oral tablet

  • Bempedoic AcidDrug

    Oral capsule

  • Placebo for EnlicitideOther

    enlicitide-matching placebo oral tablet

  • Placebo for EzetimibeOther

    ezetimibe-matching placebo oral tablet

  • Placebo for Bempedoic AcidOther

    bempedoic acid-matching placebo oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56Time frame: Baseline and Day 56

Locations

35 sites in 8 countries. Site status is shown where the registry gives one.

  • Clinical Trials Research ( Site 1509)

    Lincoln, California

  • Healthcare Research Network - Chicago ( Site 1507)

    Flossmoor, Illinois

  • L-MARC Research Center ( Site 1501)

    Louisville, Kentucky

  • Velocity Clinical Research Rockville ( Site 1503)

    Rockville, Maryland

  • Velocity Clinical Research, Gulfport ( Site 1505)

    Gulfport, Mississippi

  • Piedmont Research Partners ( Site 1506)

    Fort Mill, South Carolina

  • Rainier Clinical Research Center ( Site 1502)

    Renton, Washington

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 1002)

    Mar del Plata, Buenos Aires, Argentina

  • CIPREC-CIPREC Sede Arenales ( Site 1000)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Fundacion Estudios Clinicos ( Site 1001)

    Rosario, Santa Fe Province, Argentina

  • The Medical Arts Health Research Group ( Site 1606)

    Vancouver, British Columbia, Canada

  • Cambridge Cardiac Care Centre ( Site 1603)

    Cambridge, Ontario, Canada

  • North York Diagnostic and Cardiac Centre ( Site 1605)

    North York, Ontario, Canada

  • Institut de Cardiologie de Montreal ( Site 1604)

    Montreal, Quebec, Canada

  • Diex Recherche Trois-Rivieres ( Site 1602)

    Trois-Rivières, Quebec, Canada

  • Hôpital Bichat - Claude-Bernard ( Site 0504)

    Paris, France

  • Hôpital Arnaud de Villeneuve - CHU Montpellier ( Site 0505)

    Montpellier, Herault, France

  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes-CIC Endocrinology-Diabetology-Nutrition ( Sit

    Nantes, Loire-Atlantique, France

  • Hospices Civils de Lyon - Hopital Louis Pradel ( Site 0501)

    Bron, Rhone, France

  • Yitzhak Shamir Medical Center. ( Site 0702)

    Beer Yaakov, Israel

  • Assuta Beersheba MC ( Site 0704)

    Beersheba, Israel

  • Rambam Health Care Campus ( Site 0700)

    Haifa, Israel

  • Meir Medical Center. ( Site 0703)

    Kfar Saba, Israel

  • EAP Sardenya ( Site 0800)

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron ( Site 0803)

    Barcelona, Spain

  • Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 0801)

    Málaga, Andalusia, Spain

  • Hospital de Figueres ( Site 0804)

    Figueres, Gerona, Spain

  • Hospital San Rafael de Coruna ( Site 0805)

    A Coruña, La Coruna, Spain

  • National Cheng Kung University Hospital-Internal Medicine ( Site 0403)

    Tainan, Taiwan

  • National Taiwan University Hospital ( Site 0400)

    Taipei, Taiwan

  • Taipei Veterans General Hospital-Department of Medicine ( Site 0402)

    Taipei, Taiwan

  • Chang Gung Medical Foundation-Linkou Branch ( Site 0404)

    Taoyuan, Taiwan

  • Barts Health NHS Trust-William Harvey Clinical Research Centre ( Site 0901)

    London, England, United Kingdom

  • Royal Free Hospital ( Site 0900)

    London, England, United Kingdom

  • National Institute for Health Research UCLH Clinical Research Facility ( Site 0908)

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.